Jerini Submits Icatibant NDA; Asks FDA For Priority Review
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.
Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.